EP Patent

EP2341912A2 — Method of treatment of attention deficit/hyperactivity disorder (adhd)

Assigned to Supernus Pharmaceuticals Inc · Expires 2011-07-13 · 15y expired

What this patent protects

The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.

USPTO Abstract

The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.

Drugs covered by this patent

viloxazine-hydrochloride (VILOXAZINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP2341912A2
Jurisdiction: EP
Classification: —
Expires: 2011-07-13
Drug substance claim: No
Drug product claim: No
Assignee: Supernus Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.